POLISCOPE
Back to feed
Part ofHealth →

The civic record

Read. Follow. Verify.

National Sickle Cell Awareness Month, 2024

Record date · August 30, 2024

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

What This Bill Does

President Biden has proclaimed September 2024 as National Sickle Cell Awareness Month to highlight the impact of Sickle Cell Disease (SCD) on Americans. The proclamation outlines federal efforts to improve treatment access, support clinical research, and address for those living with the condition.

Why it matters

This document outlines the current federal administrative focus and resource allocation regarding the treatment and management of Sickle Cell Disease.

Who It Affects

Groups the bill's text affects, as described in the record. Being affected is not a position for or against it.

Directly affected

Individuals with Sickle Cell Disease

The administration is implementing changes to Medicare and Medicaid access for gene therapy treatments and expanding community-based care resources.

Directly affected

Healthcare providers

Providers are subject to new data collection and coordination efforts managed by federal agencies to improve integrated care.

Key Facts

  • Approximately 100,000 Americans live with Sickle Cell Disease.
  • The FDA approved the first gene therapies for SCD last year.
  • SCD disproportionately affects Black and Hispanic Americans.
  • Federal agencies are working to increase access to gene therapy treatments via Medicare and Medicaid.

Frequently Asked Questions

What is the purpose of National Sickle Cell Awareness Month?
The month is intended to recommit to finding a cure, supporting those with the disease, and addressing in communities.
What specific actions is the administration taking regarding SCD?
The administration is funding clinical trials, expanding access to gene therapies through Medicare and Medicaid, and improving data collection to better target resources.

What else do you want to know?

News Coverage

Full breakdown

Who this bill affects and the strongest case for and against it, written only from the bill’s own text.

Discoveries

1 pattern noticed across the record

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Focus on Gene Therapy Access

The administration is explicitly linking Medicare and Medicaid policy to the accessibility of new gene therapy treatments for SCD.

Connected Entities

Office of the National Coordinator for Health Information Technology, Centers for Disease Control and Prevention, Health Resources and Services Administration and 3 more

Sources

Open source document

www.federalregister.gov

Analysis Score

0–100
  • Significance40
    How much this matters to a regular citizen
  • Controversy5
    Intensity of disagreement among stakeholders
  • Entertainment5
    Compellingness for a non-policy-wonk reader
  • Buzz10
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record